Hemophilia causes a protein deficiency in the blood, which prevents clots from forming. Patients like Mark frequently experience spontaneous internal bleeding. More
Partner Case Study
Pfizer & NCC Assist Underserved Patients
Robert B. Landry
Pfizer partners with the National Cancer Coalition to provide medicine access to underserved patients in the developing world. Over the years, NCC and Pfizer have collaborated to provide significant donations in which thousands of patients with serious diseases like cancer, hemophilia, depression and other illnesses have received the therapies that they require for good health. One example is the donation of over 24 million international units of ReFacto® Antihemophilic Factor (Recombinant), a therapy used for the treatment and prevention of bleeding in individuals with hemophilia A. Along with Pfizer's BeneFIX therapy for Hemophilia B type patients, these donations have helped hundreds of boys and young men in the developing world with these rare genetic diseases, who would have had limited or no access to these required life-saving treatments.
“Pfizer is dedicated to developing and delivering innovative hemophilia therapies and we are proud of our partnership with the National Cancer Coalition, which is helping to distribute Pfizer-donated factor product to patients in the global hemophilia community,” says Jean-Michel Halfon, President and General Manager, Emerging Markets, Pfizer. “We are committed to working with partner organizations like NCC to provide access to hemophilia medicines to patients who need them most.”
NCC, a non-governmental organization (NGO), is a preferred partner of Pfizer. NCC has a unique network, capabilities, and relationships with hundreds of developing-world physicians and public medical facilities to be able to implement this type of specialty medicine donation initiative. ReFactoÂ® requires refrigeration and special logistics and handling to be able to be properly shipped overseas and then handled once it is received in the developing world. NCC works closely with our overseas partner hospitals to ensure that our donations of specialty pharmaceuticals are properly stored and remain efficacious.
The value of these life-saving donation is tremendous, as they provide vital hope and healing for many hundreds of hemophilia patients in the developing world in countries such as: Belize, Colombia, the Dominican Republic, El Salvador, Honduras, Guatemala, Jamaica, Mexico, Moldova, Nicaragua, Panama, Paraguay, the Philippines, and Tanzania. In addition to the hemophilia program, the National Cancer Coalition and Pfizer have collaborated together in programs to provide access to cancer, antibiotics, arthritis, and depression. In the past few years, Pfizer has generously donated over $50 million worth of chronic disease and specialty medicines to NCC to assist underserved patients within the developing world.
“Our organization is dedicated to providing the resources and tools needed in the treatment and prevention of cancer, hemophilia, depression, and other serious diseases and illnesses throughout the world,” says Robert Landry, President of the National Cancer Coalition. “Product donations such as Pfizer’s are essential to addressing the needs of the patients and families that we serve globally.”
Hemophilia is a rare, inherited blood-clotting disorder characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. People with hemophilia A are deficient in a key protein—factor VIII—that is vital in the clotting mechanism to prevent bleeding. Patients with hemophilia A and hemophilia B are dependent on Factor VIII and Factor IX replacement therapy, respectively.
Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com
The Dominican Republic
Specific Brand Names
Pfizer and NCC
NCC and Pfizer representatives at a Valdezan mental health hospital in Lima.
- Jean-Michel Halfon, President and GM, Emerging Markets, Pfizer